Bio Life Tech Venture Capital Conference In Brief
This article was originally published in The Gray Sheet
Executive Summary
NeoDiagnostix: Cervical DNA Dtex Pap screening follow-up cervical cancer test will be directly marketed to clinical reference labs in 2006, bypassing the need for FDA approval, CEO Gregory Endress says Sept. 14 during the Bio Life Tech Venture Capital Conference in Baltimore, Md. The firm's test is targeted at the 3.5 mil. abnormal Pap tests recorded each year and is intended to complement existing HPV tests such as Ventana Medical'sInform, Cytyc's ThinPrep and Digene's DNAwithPap. Cervical Dtex is based on fluorescent in situ hybridization (FISH) technology, which the firm will also use in an oral cancer diagnostic by 2007. NeoDiagnostix expects revenues of $5 mil. in 2006...